Meanwhile, PI3K signal transduction interacts with Wnt, Mitogen-Activated Protein Kinase (MAPK), and AR signaling cascades, synergistically driving prostate cancer growth and therapy resistance, indicating that pathway inhibitors hold broad application potential in prostate cancer [28]. This evidence concerns the gene WNK2 and prostate carcinoma.